2. Search Result
Search Result
Results for "

Antiobesity Effect

" in MedChemExpress (MCE) Product Catalog:

17

阻害剤およびアゴニスト

5

ペプチド

7

天然物

製品番号 製品名 Target 研究分野 構造式
  • HY-108521
    HX531

    		RAR/RXR Apoptosis MDM-2/p53 Metabolic Disease Cancer
    HX531 is an orally active RXR antagonist with an IC50 of 18 nM. HX531 upregulates the p53-p21Cip1 pathway. HX531 abrogates the anti-apoptotic effect of t-RA. HX531 exerts anti-obesity, anti-diabetic and anti-melanoma activities .
    HX531
  • HY-N6871
    Abietic acid
    3 Publications Verification

    		 Bacterial IKK Ferroptosis Infection Metabolic Disease Inflammation/Immunology Cancer
    Abietic acid, an orally active diterpene isolated from Colophony, displays significant anti-proliferative, anti-inflammatory, anti-obesity effect, bacteriostatic, cell cycle arresting and pro-apoptotic activities. Abietic acid inhibits lipoxygenase activity for allergy. Abietic acid enhances cell migration and tube formation in HUVECs. Abietic acid induces significant angiogenic potential, which is associated with upregulation of extracellular signal-regulated kinase (ERK) and p38 expression. Abietic acid attenuates sepsis-induced lung injury by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway to inhibit M1 macrophage polarization. Abietic acid exhibits a positive effect against liver injury by attenuating inflammation and ferroptosis. Abietic acid shows accelerated wound closure in a mouse model of cutaneous wounds. Abietic acid significantly reduces the proliferation and growth of NSCLC cells by IKKβ inhibition.Additionally, Abietic acid ameliorates psoriasis-like inflammation and modulates gut microbiota in mice. Abietic acid is promising for research in non-small-cell lung cancer (NSCLC), liver injury-related deseases and psoriasis .
    Abietic acid
  • HY-N1411
    Platycodin D
    Maximum Cited Publications
    8 Publications Verification

    		 AMPK Wnt Metabolic Disease
    Platycodin D is a saponin isolated from Platycodon grandiflorus, acts as an activator of AMPKα, with anti-obesity property. WNT/β-catenin pathway mediates the anti-adipogenic effect of platycodin D .
    Platycodin D
  • HY-P10377
    GUB03385

    		Neuropeptide FF Receptor Metabolic Disease
    GUB03385 is a long-acting PrRP31 analogue. GUB03385 is a potent dual agonist for GPR10 (full agonist, EC50: 0.4 nM) and NPFF2R (partial agonist, EC50: 20 nM). GUB03385 has anti-obesity effect .
    GUB03385
  • HY-16942
    Damulin B
    1 Publications Verification

    		 Apoptosis Reactive Oxygen Species (ROS) Bcl-2 Family CDK MMP Interleukin Related MDM-2/p53 Metabolic Disease Inflammation/Immunology Cancer
    Damulin B is a dammarane-type saponin found in Gynostemma pentaphyllum. Damulin B can inhibit cancer cell apoptosis, decrease mitochondrial membrane potential, inhibit ROS production and cause G0/G1 phase arrest. Damulin B can prevent Cisplatin (HY-17394)-induced acute kidney injury and induce hair growth. Damulin B shows anti-inflammation anti-diabetic and anti-obesity effect. Damulin B can be used for the researches of cancer, inflammation, metabolic disease, such as lung cancer, osteoarthritis and diabetes .
    Damulin B
  • HY-P11291A
    NNC0165-1273 TFA

    		Neuropeptide Y Receptor Metabolic Disease
    NNC0165-1273 (TFA) is the trifluoroacetic acid of NNC0165-1273 (HY-P11291). NNC0165-1273 is an analog of gut hormone peptide YY (PYY3-36). NNC0165-1273 has a superior affinity for Y2 receptor over Y1, Y4, and Y5 receptor. NNC0165-1273 has a potent anorectic effect and significantly reduces nighttime and ghrelin-induced food intake by producing early satiety. NNC0165-1273 inhibits ghrelin-induced cFos expression in NPY/AgRP neurons. NNC0165-1273 can be used for antiobesity therapies research .
    NNC0165-1273 TFA
  • HY-P1297
    CRF(6-33)(human)

    		CRFR Neurological Disease
    CRF(6-33)(human) is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) has anti-obesity effect .
    CRF(6-33)(human)
  • HY-N1411R
    Platycodin D (Standard)

    		Reference Standards AMPK Wnt Metabolic Disease
    Platycodin D (Standard) is the analytical standard of Platycodin D. This product is intended for research and analytical applications. Platycodin D is a saponin isolated from Platycodon grandiflorus, acts as an activator of AMPKα, with anti-obesity property. WNT/β-catenin pathway mediates the anti-adipogenic effect of platycodin D .
    Platycodin D (Standard)
  • HY-111431R
    p-Cresyl sulfate (Standard)

    p-Tolyl sulfate (Standard)

    		 Reference Standards JNK p38 MAPK Reactive Oxygen Species (ROS) Metabolic Disease
    Platycodin D (Standard) is the analytical standard of Platycodin D. This product is intended for research and analytical applications. Platycodin D is a saponin isolated from Platycodon grandiflorus, acts as an activator of AMPKα, with anti-obesity property. WNT/β-catenin pathway mediates the anti-adipogenic effect of platycodin D .
    p-Cresyl sulfate (Standard)
  • HY-N8989
    (1,5E,11E)-Tridecatriene-7,9-diyne-3,4-diacetate

    		Lipase Metabolic Disease
    (1,5E,11E)-Tridecatriene-7,9-diyne-3,4-diacetate, isolated from the ethanol extract of Atractylodes lancea rhizome, displays significant lipase inhibition with an IC50 value of 23.9 µg/mL. Antiobesity Effect .
    (1,5E,11E)-Tridecatriene-7,9-diyne-3,4-diacetate
  • HY-157534
    Pancreatic lipase-IN-2

    		Lipase Metabolic Disease
    Pancreatic lipase-IN-2 (compound 7r) is a potent inhibitor of pancreatic lipase (PL), with the IC50 value of 2.67 μM, that has anti-obesity effect .
    Pancreatic lipase-IN-2
  • HY-B1419R
    Salicyl alcohol (Standard)

    2-Hydroxybenzyl alcohol (Standard); Saligenin (Standard)

    		 Drug Intermediate Reference Standards Others
    Soyasaponin Aa (Standard) is the analytical standard of Soyasaponin Aa. This product is intended for research and analytical applications. Soyasaponin Aa is a soyasaponin that exerts an anti-obesity effect in 3T3-L1 adipocytes through downregulation of peroxisome proliferator-activated receptor γ (PPARγ) .
    Salicyl alcohol (Standard)
  • HY-P1297A
    CRF(6-33)(human) TFA

    		CRFR Neurological Disease
    CRF(6-33)(human) TFA is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) TFA competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) TFA has anti-obesity effect .
    CRF(6-33)(human) TFA
  • HY-13766
    Timcodar

    VX-853

    		 PPAR Others
    Timcodar is a macrolide agent, and studies have shown that during adipogenesis, timcodar can significantly inhibit fat accumulation, with an effect similar to that of rapamycin. However, unlike rapamycin, timcodar does not cause immunosuppression and glucose resistance. In addition, timcodar can effectively inhibit the adipogenic transcriptional regulators PPAR?? and C/EBP??, thereby inhibiting genes involved in fat accumulation. These studies lay the foundation for timcodar as a potential anti-obesity therapy, as obesity is becoming a global epidemic.
    Timcodar
  • HY-162703
    Lipid-lowering agent-2

    		AMPK Metabolic Disease
    Lipid-lowering agent-2 (Compound 14d) is an orally active lipid-lowering agent with an EC50 of 0.06 μM. Lipid-lowering agent-2 inhibits the lipid synthesis, activates the AMPK signaling pathway, and exhibits anti-obesity effect. Lipid-lowering agent-2 inhibits food intake, improves the glucose metabolism, and reduces the body weight and adipose tissue in high-fat diet (HFD)-induced obese mice .
    Lipid-lowering agent-2
  • HY-P11291
    NNC0165-1273

    		Neuropeptide Y Receptor Endocrinology
    NNC0165-1273 is an analog of gut hormone peptide YY (PYY3-36). NNC0165-1273 has a superior affinity for Y2 receptor over Y1, Y4, and Y5 receptor. NNC0165-1273 has a potent anorectic effect and significantly reduces nighttime and ghrelin-induced food intake by producing early satiety. NNC0165-1273 inhibits ghrelin-induced cFos expression in NPY/AgRP neurons. NNC0165-1273 can be used for antiobesity therapies research .
    NNC0165-1273
  • HY-108521R
    HX531 (Standard)

    		Reference Standards RAR/RXR Apoptosis MDM-2/p53 Metabolic Disease Cancer
    HX531 (Standard) is the analytical standard of HX531 (HY-108521). This product is intended for research and analytical applications. HX531 is an orally active RXR antagonist with an IC50 of 18 nM. HX531 upregulates the p53-p21Cip1 pathway. HX531 abrogates the anti-apoptotic effect of t-RA. HX531 exerts anti-obesity, anti-diabetic and anti-melanoma activities .
    HX531 (Standard)

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

タイトル

  

国或いは地域 *

お名前 *

 

組纖名 *

デパートメント *

     

メールアドレス *

 

製品名 *

製品番号

  

カスタマ需要量 *

電話番号 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: